DMK Pharmaceuticals Announces Presentation Of Preclinical Results Comparing Effects Of DPI-125 On Opioid Withdrawal Behaviors Versus Standard Of Care For Opioid Use Disorder At SfN Neuroscience 2023
DMK Pharmaceuticals Announces Presentation Of Preclinical Results Comparing Effects Of DPI-125 On Opioid Withdrawal Behaviors Versus Standard Of Care For Opioid Use Disorder At SfN Neuroscience 2023
DMK Pharmaceuticals Corporation (NASDAQ:DMK), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders, today announced the presentation of preclinical results comparing the effects of DPI-125 on opioid withdrawal behaviors to methadone and buprenorphine, the standard of care for opioid use disorder (OUD), in a poster session at the Society for Neuroscience Annual Meeting (SfN Neuroscience 2023) held November 11-13, 2023 in Washington D.C. DPI-125 is a novel, small-molecule triple (mu, delta and kappa) opioid receptor agonist, being developed for the treatment of opioid use disorder.
DMK Pharmicals Corporation（納斯達克股票代碼：DMK）是一家商業階段的神經生物技術公司，主要專注於開發和商業化用於治療阿片類藥物過量和藥物濫用障礙的產品。該公司今天在神經科學學會年會（SFF）的海報發佈會上宣佈，將 DPI-125 對阿片類藥物戒斷行爲的影響與阿片類藥物使用障礙（OUD）的治療標準美沙酮和****進行了比較的臨床前結果 n Neuroscience 2023) 於 2023 年 11 月 11 日至 13 日在華盛頓特區舉行。DPI-125 是一場正在開發用於治療阿片類藥物使用障礙的新型小分子三聯阿片類藥物受體激動劑。
"Only about 12% of patients receive treatment for OUD, despite the proven efficacy of current medications. Buprenorphine, the market leader with US sales in excess of $3B in 2022, requires an induction phase to induce withdrawal symptoms prior to initiating the first dose. It is challenging for a patient to voluntarily experience these symptoms. In addition, buprenorphine can be abused. For this and other reasons, widespread adoption is low. We believe that DPI-125, our novel clinical stage compound, will be able to overcome this and several other barriers to treatment initiation and maintenance. The positive data to be presented today marks the first step to realizing this promise," said Eboo Versi, M.D., Ph.D., CEO of DMK Pharmaceuticals. "We are excited to present preclinical data comparing DPI-125, a triple opioid agonist, to the standard of care treatments buprenorphine and methadone to alleviate withdrawal symptoms. This preclinical study was financially supported by a grant from the National Institute of Drug Abuse (NIDA), and we believe that it warrants further development."
“儘管目前的藥物已得到證實，但只有大約12％的患者接受了OUD治療。****是市場領導者，2022年在美國的銷售額超過30億美元，在開始服用第一劑之前，需要進入誘導階段才能誘發戒斷症狀。對於患者來說，自願出現這些症狀是一項艱鉅的任務。此外，****可能會被濫用。由於這個和其他原因，廣泛採用率很低。我們相信，我們的新型臨床階段化合物 DPI-125 將能夠克服這一障礙以及其他幾個阻礙開始和維持治療的障礙。今天公佈的積極數據標誌着實現這一承諾的第一步。” DMK Pharmicalsi首席執行官兼醫學博士、博士說。“我們很高興提供臨床前數據，將三聯阿片類藥物激動劑 DPI-125 與緩解戒斷症狀的標準護理療法****和美沙酮進行比較。這項臨床前研究得到了美國國家藥物濫用研究所（NIDA）的資助，我們認爲它值得進一步發展。”
Details of the poster are as follows:
海報的詳細信息如下：
Title: Effect of DPI-125 on opioid withdrawal behaviors in rats: a comparison study with
methadone and buprenorphine
Program Number / Poster Number: Poster 297.01 / SS14
Session Title: G.09. Drugs of Abuse and Addiction
Session Date, Time: Monday, November 13, 2023, 1:00 p.m. - 5:00 p.m. ET
Presenter: Adam Mar, Ph.D., Assistant Professor, Department of Neuroscience and Physiology at NYU Grossman School of Medicine
Location: WCC Halls A-C
標題： DPI-125 對大鼠阿片類藥物戒斷行爲的影響：與之比較研究
美沙酮和****
節目編號/海報編號： 海報 297.01 /SS14
會議標題： G.09。濫用和成癮藥物
會議日期、時間： 2023 年 11 月 13 日星期一，美國東部時間下午 1:00 至下午 5:00
演示者： Adam Mar，博士，紐約大學格羅斯曼醫學院神經科學與生理學系助理教授
地點： WCC 大廳 A-C
The poster will be available on DMK's website following the presentation session.
演講會結束後，海報將在DMK的網站上公佈。
For more details about the Society for Neuroscience Annual Meeting, please visit:
有關神經科學學會年會的更多詳情，請訪問：
譯文內容由第三人軟體翻譯。